Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
396 Leser
Artikel bewerten:
(1)

Fishawack Health unveils an unrivaled global market access and HEOR offering with the acquisition of PRMA Consulting

Fishawack Health bolsters its strong strategic offering by acquiring PRMA Consulting - a global market access and HEOR consulting leader with significant expertise in US, EU, and Asia-Pacific markets

LONDON, March 24, 2021 /PRNewswire/ -- Leading life science commercialization partner Fishawack Health has acquired PRMA Consulting, a premier global market access and health economics outcomes research (HEOR) consultancy with offices across Europe, Asia, and the US.

(From left to right) Jayne Sykes, Partner; David Sykes, Founding Partner; and Sotiria Papanicolaou, Partner, lead the PRMA Consulting team

The acquisition bolsters Fishawack Health's strong strategic offering, adding deep expertise in Asia-Pacific and European markets to complement the company's existing market access offering in North America. Fishawack Health now offers one of the industry's leading market access and HEOR capabilities, spanning the globe.

"We're delighted to welcome PRMA Consulting to our group - our third acquisition of 2021," Oliver Dennis, Fishawack Health Co-founder, and CEO, said. "PRMA Consulting brings extensive global market access, HEOR, and disease area expertise, making them an important addition to our Consulting business unit. By acquiring best-in-class organizations like PRMA Consulting, we are continuously developing agile, integrated, and tailored solutions that ensure we're one step ahead of our client's complex and evolving needs across the product lifecycle - from laboratory assets to launch and beyond."

For more than a decade, PRMA Consulting has shaped the future of market access with an industry-leading strategic offering and award-winning, cloud-based digital applications that unlock and optimize product value - the PRMA Healthcheck, PRMA Navigator, PRMA Tracker, and PRMA Access Accelerator. Fishawack Health intends to make these solutions available to all existing clients.

Fishawack Health Head of Consulting, Fred Bassett, said: "Our goal at Fishawack Health is to give clients access to highly-experienced experts who provide strategic direction, helping to make decisions that matter across the development and commercialization of portfolios, products, and services. The PRMA Consulting team shares our passion for solving the most complex and challenging healthcare problems in fast-evolving markets. We're delighted to add a team of market access and health economics strategists with deep specialism in HEOR, healthcare technology assessments, pricing, and reimbursement processes."

David Sykes, Founding Partner at PRMA Consulting, explained: "We are excited about the opportunity of joining Fishawack Health and building out the leading global value, evidence, and access group. We were drawn by our shared culture and values and the ability to tap into existing complementary Fishawack Health resources, which will help us provide our clients with an even better experience.

"As the pace of clinical development accelerates and the responsibilities between medical, commercial, access, and HEOR merge, we see a huge opportunity to develop market-leading integrated and cross-functional service offerings for our clients.

"We would like to thank our clients for helping us achieve this important milestone. I would also like to recognize and thank the wonderful team at PRMA Consulting who have helped us to be so successful. As our journey progresses, we remain focused on partnering with clients to help them enable faster patient access to therapies that improve health outcomes."

About Fishawack Health
Visit:?www.fishawack.com?

About PRMA Consulting
Visit: www.prmaconsulting.com

Advisers involved in this transaction included:
KPMG Manchester acted on behalf of Fishawack Health for financial and tax due diligence; Craig Scott and Elan Iorwerth, Hill Dickinson (Liverpool), together with Jamie Mercer and Lyle LeBlang, Sheppard Mullin (San Diego), and Allen & Overy (London) provided legal support; and EY provided tax advice. PricewaterhouseCoopers acted on behalf of PRMA Consulting for corporate finance. Charles Russell Speechlys LLP provided legal support and due diligence, and Marcussen Consulting LLP provided Tax advice and due diligence.

Photo - https://mma.prnewswire.com/media/1471132/Fishawack_Health_Picture1.jpg

© 2021 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.